DUBLIN–(BUSINESS WIRE)–The “Primary
Immune Deficiency (PID) – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.
Primary Immune Deficiency (PID) – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Primary Immune Deficiency (PID) (Genetic Disorders), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide
also reviews of key players involved in therapeutic development for
Primary Immune Deficiency (PID) and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II,
Preclinical and Discovery stages are 1, 1, 8, 3, 8 and 1 respectively.
Similarly, the Universities portfolio in Phase II, Phase I and
Preclinical stages comprises 8, 1 and 5 molecules, respectively.
Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Primary Immune Deficiency (PID) (Genetic Disorders). -
The pipeline guide reviews pipeline therapeutics for Primary Immune
Deficiency (PID) (Genetic Disorders) by companies and
universities/research institutes based on information derived from
company and industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Primary Immune
Deficiency (PID) (Genetic Disorders) therapeutics and enlists all
their major and minor projects. -
The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic
Disorders) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)
Key Topics Covered:
- Introduction
- Primary Immune Deficiency (PID) – Overview
- Primary Immune Deficiency (PID) – Therapeutics Development
- Primary Immune Deficiency (PID) – Therapeutics Assessment
-
Primary Immune Deficiency (PID) – Companies Involved in Therapeutics
Development - Primary Immune Deficiency (PID) – Drug Profiles
- Primary Immune Deficiency (PID) – Dormant Projects
- Primary Immune Deficiency (PID) – Discontinued Products
- Primary Immune Deficiency (PID) – Product Development Milestones
- Appendix
Companies Mentioned
- ADMA Biologics Inc
- Biotest AG
- GC Pharma
- GigaGen Inc
- Novartis AG
- Octapharma AG
- Orchard Therapeutics Plc
- ProMetic Life Sciences Inc
- Sangamo Therapeutics Inc
- Taiga Biotechnologies Inc
- Takeda Pharmaceutical Co Ltd
- X4 Pharmaceuticals Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kzs3o7
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs